Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Rani Therapeutics (Nasdaq: RANI) announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 2:30 p.m. ET in Boston, MA.

Rhea-AI Summary

Rani Therapeutics (Nasdaq: RANI) announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 2:30 p.m. ET in Boston, MA. The Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas, will deliver a presentation and hold 1x1 meetings. A live webcast and replay will be available via the Investor Relations section of the company’s website.

Argus Aug 10 session 2 alerts

-1.91% close to close 0.4x rel. volume Open Argus

Details

News Market Reaction – RANI

$92.59M Market Cap

On Aug 10, the day this news came out, RANI closed 1.91% below the previous close. Our momentum scanner recorded 2 alerts in the available session data.

Data tracked by StockTitan Argus for the Aug 10 session.

Market Context

Recent insider data recorded 71,000 shares bought and 0 sold across two transactions, adding ownersh...

Analysis

Recent insider data recorded 71,000 shares bought and 0 sold across two transactions, adding ownership context to the conference notice. The active S-3 is a resale registration, and presentation disclosures remain the key watchpoint.

Key Figures

Conference edition: 46th Conference date: August 12, 2026 Presentation time: 2:30 p.m. ET +1 more

Conference edition

46th

Canaccord Genuity Annual Growth Conference

Conference date

August 12, 2026

Scheduled presentation date

Presentation time

2:30 p.m. ET

Scheduled conference presentation

Meeting format

1x1 meetings

Conference participation format

Historical Context

5 past events · Latest: Aug 04

5 events

1. Aug 04

   Board appointment

   24h Move

   +2.3%

   Michelle Gilson joined the board and became Audit Committee chair.

2. Jul 20

   Inducement grant

   24h Move

   +0.7%

   New CFO received an option grant covering 2,000,000 Class A shares.

3. Jul 15

   Phase 1a data

   24h Move

   +4.3%

   RT-114 oral bioavailability exceeded matched subcutaneous dosing in volunteers.

4. Jul 09

   R&D collaboration

   24h Move

   -1.6%

   PegBio collaboration expanded oral delivery research across obesity candidates.

5. Jun 29

   CFO appointment

   24h Move

   +3.9%

   Nicholas Maestas became Chief Financial Officer with immediate effect.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

biologics, 1x1 meetings

2 terms

biologics medical

"clinical-stage biotherapeutics company focused on oral delivery of biologics"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

1x1 meetings financial

"Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas"

1x1 meetings are private, one-on-one conversations between a company's leaders and investors or stakeholders. These meetings provide a dedicated space to discuss company performance, future plans, and concerns in detail. For investors, they offer a clearer understanding of management’s strategies and priorities, helping inform their investment decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:

Canaccord Genuity 46th Annual Growth Conference
Date: Wednesday, August 12, 2026 at 2:30pm E.T.
Location: Boston, MA
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas
Format: Presentation and 1x1 Meetings

Interested parties can access the live webcast for this conference from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replay will be available after the conclusion of the presentation.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill^® Capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill^® Capsule technology.

Investor Contact:
investors@ranitherapeutics.com  

Media Contact:
media@ranitherapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Rani Therapeutics (RANI) present at the Canaccord Genuity 46th Annual Growth Conference?

Rani Therapeutics will present on Wednesday, August 12, 2026 at 2:30 p.m. ET. According to Rani Therapeutics, the session is part of the Canaccord Genuity 46th Annual Growth Conference held in Boston, MA, and includes a presentation plus 1x1 meetings.

Where is the Canaccord Genuity 46th Annual Growth Conference featuring Rani Therapeutics (RANI) being held?

The conference featuring Rani Therapeutics is being held in Boston, MA. According to Rani Therapeutics, its CEO and CFO will participate with a formal presentation and 1x1 investor meetings scheduled for August 12, 2026 at 2:30 p.m. ET.

Who will present for Rani Therapeutics (RANI) at the Canaccord Genuity 46th Annual Growth Conference?

Rani Therapeutics will be presented by CEO Talat Imran and CFO Nicholas Maestas. According to Rani Therapeutics, they will deliver a conference presentation and participate in 1x1 meetings with investors during the Boston event on August 12, 2026.

How can investors access the Rani Therapeutics (RANI) webcast from the Canaccord Genuity 46th Annual Growth Conference?

Investors can access the live webcast through the Investor Relations section of Rani Therapeutics’ website. According to Rani Therapeutics, a webcast replay will also be available online after the conclusion of the company’s conference presentation.

Will a replay of Rani Therapeutics’ (RANI) presentation at the Canaccord Genuity conference be available?

Yes, a replay of the Rani Therapeutics presentation will be available after the event. According to Rani Therapeutics, investors can access the webcast replay from the Investor Relations section of the company’s website following the August 12, 2026 session.